Escolar Documentos
Profissional Documentos
Cultura Documentos
Degenerative phase
Heterogeneity of MS Pathology
Antibodies
T-cells + Macrophages
OligodendrocyteDystrophy
Myelin Scarring
Electric pulse Oligodendrocyte
Sclerosis (scarring)
MS: Histopathology
Copyright 1998 Massachusetts Medical Society. All rights reserved
Adapted with permission from Waxmann SG. N Engl J Med 1998;338:32325; and Trapp BD et al. N Engl J Med 1998;338:27885
Demyelination induced: 1. Increased vulnerability to damage of demyelinated axons 2. Dying back mechanism
Genetic determination: 1. Genetic programme 2. Degeneration Apoptotic mechanisms: 1. Caspase pathway 2. Other
Depletion of growth factors: 1. Depletion of stem cells 2. Lack of inflammatory cells which may produce GF
What is Neuroprotection?
Neuroprotection
Prevention of the original insult
Neuroregeneration
Recovery of neuronal cells (or functional neuronal connections) after injury
Demyelination induced: 1. Increased vulnerability to damage of demyelinated axons 2. Dying back mechanism
Genetic determination: 1. Genetic programme 2. Degeneration Apoptotic mechanisms: 1. Caspase pathway 2. Other
Depletion of growth factors: 1. Depletion of stem cells 2. Lack of inflammatory cells which may produce GF
iNOS inhibitors
Calpain inhibitors Free radical scavengers Anti-apoptotic therapies (e.g. caspase inhibitors) Na+ channel- or Na+/Ca++-exchanger inhibitors
Anti-inflammation
Neuroprotection
Future Treatment of MS
Evidence that the changes observed in late stages are at least partially pre-determined by early (inflammatory) events As early as possible?